Immune Profile Study in Women Aged 18 to 40 With Chronic Pelvic Pain Resistant to Hormone Treatment

What this Trial Is About

Researchers are studying chronic pelvic pain CPP, a condition affecting more than one in four women, particularly those with endometriosis who have not responded to hormone treatments. The study aims to identify specific immune profiles by measuring various cytokines after stimulating immune cells, to better understand immune imbalances in CPP. Participants include women aged 18 to 40 who have been on continuous hormone therapy for at least six months. They are divided into two groups those with chronic pelvic pain resistant to hormone therapy and asymptomatic patients undergoing hormone therapy. The study measures blood levels of pro-inflammatory and anti-inflammatory cytokines following non-specific stimulation of peripheral blood cells. Participants will provide blood samples for immune profile analysis, with evaluations focused on cytokine concentrations linked to CPP, endometriosis, neuropathic pain, pelvic pain sensitization, infertility, and symptom severity. The primary outcome is to identify immune profiles over 24 months. Consent and imaging data within 12 months are required, and ongoing monitoring will track immune responses related to CPP.

Identify a Specific Immune Profile in Patients With Chronic Pelvic Pain Resistant to First-line Treatments by Measuring Th1, Th2, Th17, and Treg Cytokines Produced After Non-specific Functional Cell Stimulation - ImmunoCPP